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Background: The incidence of Moyamoya disease (MMD) in Europe is not well known. In those 
affected, the risk of brain hemorrhage is considered low. The present study aimed to investigate 
the incidence and clinical presentation of MMD in the Danish population.
Methods: Eligible patients were identified in the Danish National Patient Register from 1994 to 
2017. We collected clinical and radiological data from individual patient records from 
neurological, neurosurgical, and pediatric units across Denmark. The diagnosis was validated 
according to established criteria. We also extracted basic demographic data on the cohort from the 
Danish Civil Registration System.
Results: A total of 52 patients fulfilled the diagnostic criteria for MMD. Most cases were native 
Danes and only 15% of cases had an East Asian background. The ratio of female to male patients 
was 1.8, and the incidence had two peaks: one in childhood and another in young middle age. 
Until 2007, MMD was only diagnosed sporadically. From 2008 onwards, the incidence rate was 
0.07 per 100 000 person-years (95% confidence interval 0.05-0.09 per 100 000 person-years). The 
most common mode of presentation was ischemic stroke (33%), followed by hemorrhage (23%), 
headache (17%), and transitory ischemic attack (14%).
Conclusions: MMD is rare in Denmark, but associated with a considerable risk of hemorrhage. 
Thus, MMD should be considered in the workup for ischemic as well as hemorrhagic stroke in 
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Introduction
Moyamoya disease (MMD) is an idiopathic cerebrovascular disease characterized by progressive 
stenosis and occlusion of the distal intracranial internal carotid artery and its proximal branches1. 
As the disease progresses, small collaterals - so-called moyamoya vessels - develop at the base of 
the brain. Affected patients carry an increased risk of stroke: Ischemic lesions are a result of the 
narrowed vessels, whereas rupture of fragile collaterals may cause hemorrhage. No known causal 
treatment exists. Current management aims to reduce the risk of stroke, and unlike stroke of other 
origins, surgical revascularization plays an important role in preventing a future stroke. 
Moyamoya disease (MMD) was first reported in Japan1,2, where it remains a well-known cause of 
stroke in children as well as adults, with a reported overall incidence of 0.94 per 100 000 person-
years3. The disease occurs less frequently in other parts of the world: population-based data are 
available from the U.S4, but the epidemiology of MMD in Europe is not well described due to a 
paucity of population-based data5. Being a rare disease in Europe, affected patients are at risk of 
going undiagnosed, thus delaying appropriate treatment. Additionally, observations from Japan are 
not necessarily directly applicable to European practice, as MMD may have distinct clinical 
features in a European population6. In particular, the likelihood of hemorrhage is thought to be 
much less than in East Asia.
Using nationwide registers, the present study aims to shed light on this rare disease and describe 
its epidemiology and clinical presentation in Denmark. In a preliminary paper7, we reported an 
overall incidence of 0.047 per 100 000 person-years between 1994 and 2015. However, it was 
exclusively based on anonymous register data, which neither allowed us to validate the register 
diagnosis nor provided us with useful information on the clinical presentation of the disease. For 
the present paper, we obtained permission to access individual patient charts and radiology reports 
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Methods
All patients with a diagnosis of MMD (I67.5) between 1994 and 2017 were identified in the 
Danish National Patient Register. This register covers all hospital contacts in Denmark and is 
often used for scientific research. Discharge diagnoses and dates of discharges from all Danish 
hospitals have been recorded in the register since 1977, and from 1994, information on visits to 
outpatient clinics has been included as well8. In this way, eligible cases would be detected 
regardless of variations in referral and treatment pathways for MMD in Denmark during the study 
period. 1994 was chosen because the diagnosis first appeared in the Danish disease classification 
when the International Classification of Diseases version 10 (ICD-10) was introduced that year8. 
Furthermore, patients are registered with their unique and permanent personal identification 
number, which allowed us to extract information on all admissions and outpatient visits to Danish 
hospitals for this patient population. Among all hospital contacts, we identified the neurological, 
neurosurgical, and/or pediatric department in which the diagnosis of MMD was first made. 
Whenever a patient had been treated at a referral center, we selected the referral center for record 
review, as only referral centers (i.e., university hospitals) have a neuroradiological service with 
access to catheter angiography. From the Civil Registration System (established in 1968), we 
extracted basic demographic data (including sex, date, and place of birth) as well as information 
on whether a person is native, immigrant or descendant and, in the latter case, country of origin. 
One author (VT) visited key hospital departments and reviewed all clinical notes, clinical letters, 
and radiology reports. Data were collected on data sheets using the EpiData Entry Software 
(www.epidata.dk, The EpiData Association). Items included the date of angiography as well as 
changes in vessel caliber for individual artery segments in both the anterior and posterior cerebral 
circulation as well as the presence of moyamoya collaterals, if any. Next, the mode of presentation 
was established, and underlying conditions, if any, were recorded. Two authors (PB, consultant 
neurosurgeon with an interest in vascular neurosurgery, and PvW-M, consultant neurologist with 
an interest in vascular neurology) independently reviewed the datasheets. We used the definition 
of MMD as stated by the Research Committee on Spontaneous Occlusion of the circle of Willis 
(Moyamoya disease) in Japan9. In accordance with this definition, patients were classified as 
having definite MMD (dMMD) when having bilateral stenoses and moyamoya vessels (in 
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probable MMD (pMMD) when having stenosis and moyamoya vessels on one side or bilateral 
stenoses alone (i.e., Suzuki grade I) if we could rule out alternative diagnoses on clinical and 
radiological grounds. Patients with similar vascular changes in association with an underlying 
condition were classified as having moyamoya syndrome (MMS). When available, we reviewed 
the radiographic films before making a definite diagnosis. If the register diagnosis could not be 
confirmed, patients were excluded from further analysis. Disagreements were resolved in a 
consensus meeting. A case was defined as incident on the date of the first angiography fulfilling 
the diagnostic criteria for MMD. For the calculation of incidence, person-years were approximated 
by the number of persons at 1 January at any given calendar year. These data are accessible at 
Statistics Denmark (www.statistikbanken.dk). The prevalence at 1 Jan 2018 was also calculated. 
We did a pooled analysis of pMMD and dMMD. Separately, we also reported data on patients 
with MMS.
Statistical analysis
Analyses were performed using EpiData Analysis software (www.epidata.dk) and OpenEpi 
software (www.openepi.com). For statistics, we used the Fisher exact test and chi2 test with a 
significance level of 0.05.
Standard Protocol Approvals, Registration, and Patient Consents
The study was approved by the Danish Data Protection Agency and The Danish Patient Safety 
Authority. Patient consent was not required.
Data Availability Statement
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Results
Case validation
Seventy-six eligible patients were identified in the Danish National Patient Register (see figure 1). 
Register data from 2121 admissions or outpatient visits (including 340 contacts with a primary or 
secondary diagnosis of MMD) to Danish hospitals were reviewed. Subsequently, 13 clinical 
departments in 6 different hospitals were visited. Four additional patients were presented to us 
during site visits. Those patients were not registered with the specific code for MMD (and 
therefore they were not retrieved from the register). Of these 80 patients, two were excluded 
because the patient records could not be retrieved. Thus, charts and radiology reports from 78 
patients were available for review. A total of 52 patients fulfilled the diagnostic criteria for MMD. 
Further, 16 patients had findings consistent with MMS. In 10 cases, a diagnosis of MMD could 
not be confirmed. Two were known to have an ACTA2 gene mutation10, and two cases were 
investigated due to affected first-degree relatives, but the diagnosis was eventually ruled out; one 
patient presented with TIA and had unilateral stenosis that did not meet the diagnostic criteria, one 
patient with Fanconi anemia had an isolated stenosis of the left middle cerebral artery, and four 
cases were probably coding errors because there were no clinical features suggestive of MMD.
Demographic characteristics
There were 34 females and 18 males. A record review revealed that four of the patients were 
diagnosed with MMD before 1994. These patients were excluded from the calculation of 
incidence but were included in the other analyses. Forty patients were native Danes, 2 patients 
originated from other European countries, 8 originated from East Asia, 1 patient originated from 
Asia, and 1 patient originated from South America. Eighteen patients (35%) were younger than 18 
years at diagnosis. The age at diagnosis showed a bimodal distribution with a peak in childhood 
and another in middle-aged adults. The average age at presentation was 7 years and 40 years in 
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Until 2007, MMD was only diagnosed sporadically (figure 2). From 2008 onwards, the incidence 
rate was 0.07 per 100 000 person-years (95% confidence interval 0.05-0.09 per 100 000 person-
years). Five patients had died as of 31 December 2017. Thus, the prevalence at 1 Jan 2018 was 0.8 
per 100 000.
Angiographic features
Of the 52 patients with confirmed MMD, 36 patients had catheter angiography either at diagnosis 
or at follow-up. Fifteen patients underwent magnetic resonance angiography, whereas one patient 
underwent computed tomographic angiography. At the latest available imaging, 24 patients (46%) 
had bilateral stenoses and bilateral moyamoya vessels, 8 (15%) had bilateral stenoses and 
unilateral moyamoya vessels (5 adults and 3 children), 13 (25%) had unilateral stenosis and 
moyamoya vessels, and the remaining 7 patients (13%) had bilateral stenoses without moyamoya 
vessels. Thus, 27 patients and 25 patients were classified as having dMMD and pMMD, 
respectively (figure 1). In 11 cases (21%), posterior circulation involvement was reported.
Clinical presentation
The most common mode of presentation was ischemic stroke (33%), followed by hemorrhage 
(23%), headache (17%), and transitory ischemic attack, TIA (14%). Only one patient was 
asymptomatic at diagnosis. 8 of 12 patients with hemorrhage had bilateral disease and in 10 of 12 
patients, moyamoya vessels were detected. There was no significant difference in the mode of 
presentation between males and females. In patients younger than 18 years, more than half had 
TIA (11%) or ischemic stroke (39%) at presentation, while 11% had hemorrhage. Among patients 
18 years or older, 29% and 15% presented with ischaemic stroke and TIA, respectively, while 
29% presented with hemorrhage (figure 3). However, the difference in clinical presentation 
between the two age groups was not statistically significant.
Characteristics of cases with an East Asian background
Eight cases (4 children and 4 adults) descended from East Asia. They were equally distributed 
between the sexes. 3 cases had pMMD, and 5 had dMMD.  2 cases presented with ischemia, 2 
presented with hemorrhage, 3 presented with headache, and 1 patient presented with seizures.
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Although MMD was the main focus of this study, we also collected data on 16 patients later 
categorized as having MMS. There were 7 children and 9 adults, and 11 of the 16 patients were 
females. Neurofibromatosis was the most common associated condition, followed by Down’s 
syndrome, multiple sclerosis, Grange syndrome, Noonan syndrome, and atherosclerosis. The most 
common mode of presentation was headache (4 cases), followed by transitory ischemic attack (3 
cases), ischemic stroke (3 cases), and hemorrhage (2 cases). The indication for angiography was 
not clear in two cases, of which one was asymptomatic at diagnosis. 13 of 16 patients had bilateral 
arterial stenoses at angiography, and 14 patients had moyamoya vessels detected.
Discussion
The incidence of MMD in Europe is not well known. We know a lot more about the clinical 
features of MMD in Europeans from hospital-based surgical series11,12. However, such studies 
may be subjected to referral bias. To improve our understanding of MMD in a European setting 
we conducted a population-based study in Denmark using nationwide registers.
We found an increase in diagnosed cases between 1994 and 2017. Adopted children from East 
Asia and their descendants account partly from the rise. However, the main reason is probably an 
increased detection rate due to an increased awareness as well as improved imaging. Accessibility 
to and quality of MR imaging has improved tremendously during the study period. Also, the 
senior authors (PB and PvW-M) have given presentations on the topic in several national meetings 
in recent years. The incidence rate from 2008 onwards was 0.07 per 100 000 person-years and is 
our best estimate of the true incidence. The incidence appears to be less than one-tenth of the 
incidence of 0.94 per 100 000 person-years in Japan3 but comparable to the incidence of 0.086 per 
100 000 person-years reported in Washington state and California (U.S.A.)4. As in Japan, we 
found a bimodal age distribution.
Twenty-three percent of our cases presented with hemorrhage which is comparable to data from 
East Asia. This represents our most surprising finding. In the majority of those presenting with 
hemorrhage, bilateral diseases and moyamoya vessels were detected at angiography. Previous 
European studies have noted a striking lower proportion of cases reported to have a hemorrhagic 
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patients may have been in a poor clinical state, precluding them from referral to a large tertiary 
center. These patients will be included in a population-based study.
Migration patterns vary among European countries. This introduces a bias in the interpretation of 
our data as the incidence and possibly also the clinical features vary by race and ethnicity. We 
were able to take migration into account thanks to comprehensive nationwide registers. It should 
come as no surprise that descendants from East Asia were overrepresented in our cohort. Still, this 
group comprised only 15% of our cases and has only a modest impact on the incidence and 
prevalence of MMD in Denmark. The clinical features of these patients did not stand out from the 
rest of the cohort, so our study reflects the occurrence of MMD in a Caucasian population. 
Consequently, it should also apply to other European populations.
This work is the first population-based study on MMD in Europe. We used comprehensive 
nationwide registers and validated the diagnosis and time of onset by reviewing individual patient 
charts. The positive predictive value of the register diagnosis I67.5 (MMD and MMS) was 86%. 
The utility of the register also depends on whether a given diagnosis is coded correctly. The fact 
that we only discovered four additional cases during site visits that were not listed in the register 
suggests a high grade of completeness of the Danish National Patient Register. We included those 
cases in the cohort, so our study should include virtually all patients in Denmark diagnosed with 
MMD.
There are still a few limitations. First, we primarily evaluated and categorized cases based on 
radiology reports rather than original films. Unlike films, reports were readily accessible, 
moreover, films are only kept for a maximum of ten years. Different radiologists use descriptive 
terms differently, which may impact cohort homogeneity. However, we were able to find and 
systematically review radiological films of patients from one of four Danish university hospitals. 
We found consistency between the radiological films, radiology reports, and available clinical data 
and a similar proportion of included cases as among all patients eligible for the study. Second, 
some patients may still go undetected (false negatives). This includes asymptomatic cases, of 
which we saw only two. In Japan, asymptomatic cases comprised 17.8% of patients3. Third, 
further studies are needed to establish the clinical course and outcome of surgical intervention of 
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Conclusions
MMD is rare in Denmark, but associated with a considerable risk of hemorrhage. Thus, MMD 
should be considered in the workup for ischemic as well as hemorrhagic stroke in children and 
middle-aged Caucasians.
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Legends
Figure 1: Study flow chart
Figure 2: Annual number of incident cases
Figure 3: Disease pattern at onset
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